Synaptogenix (SNPX) Competitors $9.70 -0.69 (-6.60%) As of 07/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. KLTO, ADVM, PDSB, ANVS, ANL, GANX, NRXP, ATRA, KRON, and CELUShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Klotho Neurosciences (KLTO), Adverum Biotechnologies (ADVM), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Adlai Nortye (ANL), Gain Therapeutics (GANX), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), Kronos Bio (KRON), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Klotho Neurosciences Adverum Biotechnologies PDS Biotechnology Annovis Bio Adlai Nortye Gain Therapeutics NRx Pharmaceuticals Atara Biotherapeutics Kronos Bio Celularity Klotho Neurosciences (NASDAQ:KLTO) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Which has higher earnings and valuation, KLTO or SNPX? Klotho Neurosciences is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.36-3.56SynaptogenixN/AN/A-$12.77M-$10.08-0.96 Does the media refer more to KLTO or SNPX? In the previous week, Klotho Neurosciences had 6 more articles in the media than Synaptogenix. MarketBeat recorded 7 mentions for Klotho Neurosciences and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat Klotho Neurosciences' score of 0.59 indicating that Synaptogenix is being referred to more favorably in the news media. Company Overall Sentiment Klotho Neurosciences Positive Synaptogenix Very Positive Do insiders & institutionals have more ownership in KLTO or SNPX? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, KLTO or SNPX? Klotho Neurosciences has a beta of 11.08, indicating that its share price is 1,008% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Is KLTO or SNPX more profitable? Synaptogenix's return on equity of -115.28% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -1,779.01% -275.01% Synaptogenix N/A -115.28%-58.31% SummaryKlotho Neurosciences beats Synaptogenix on 6 of the 10 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.48M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.10%P/E Ratio-0.9620.3628.1719.69Price / SalesN/A302.79438.93100.42Price / CashN/A42.3835.5357.53Price / Book2.247.768.225.67Net Income-$12.77M-$55.11M$3.23B$257.51M7 Day Performance36.17%0.19%-0.59%-0.16%1 Month Performance147.32%10.80%6.65%9.89%1 Year Performance116.41%-0.68%26.87%15.08% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix0.3118 of 5 stars$9.70-6.6%N/A+118.4%$13.48MN/A-0.964Positive NewsKLTOKlotho NeurosciencesN/A$1.35+8.0%N/AN/A$57.57MN/A-3.75N/AADVMAdverum Biotechnologies4.402 of 5 stars$2.63-3.7%$23.80+804.9%-69.1%$57.03M$1M-0.41190PDSBPDS Biotechnology1.2949 of 5 stars$1.17-4.9%$9.00+669.2%-70.8%$56.22MN/A-1.2420News CoverageANVSAnnovis Bio1.5645 of 5 stars$2.70-5.8%$18.00+567.9%-77.6%$55.73MN/A-1.253ANLAdlai Nortye2.1051 of 5 stars$1.57+4.0%$9.00+473.2%-58.7%$55.72M$5M0.00127Positive NewsGANXGain Therapeutics2.3138 of 5 stars$1.70-8.6%$8.20+382.4%+24.6%$55.70M$50K-1.9820News CoverageNRXPNRx Pharmaceuticals2.7621 of 5 stars$3.11-3.1%$28.50+816.4%+20.4%$55.50MN/A-1.552ATRAAtara Biotherapeutics4.3918 of 5 stars$9.27-0.3%$17.75+91.5%-24.4%$55.44M$128.94M-2.49330KRONKronos BioN/A$0.88+1.5%$1.63+84.7%-41.3%$53.72M$9.85M-0.82100CELUCelularity0.1406 of 5 stars$2.48+10.7%N/A-30.5%$53.65M$54.22M-0.94220Upcoming EarningsGap DownHigh Trading Volume Related Companies and Tools Related Companies Klotho Neurosciences Alternatives Adverum Biotechnologies Alternatives PDS Biotechnology Alternatives Annovis Bio Alternatives Adlai Nortye Alternatives Gain Therapeutics Alternatives NRx Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Kronos Bio Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts